149 related articles for article (PubMed ID: 22987978)
1. Optimal therapeutic management of patients with distinct clinicopathological cancer of unknown primary subsets.
Pavlidis N
Ann Oncol; 2012 Sep; 23 Suppl 10():x282-5. PubMed ID: 22987978
[TBL] [Abstract][Full Text] [Related]
2. Docetaxel and carboplatin combination chemotherapy as outpatient palliative therapy in carcinoma of unknown primary: a multicentre Hellenic Cooperative Oncology Group phase II study.
Pentheroudakis G; Briasoulis E; Kalofonos HP; Fountzilas G; Economopoulos T; Samelis G; Koutras A; Karina M; Xiros N; Samantas E; Bamias A; Pavlidis N;
Acta Oncol; 2008; 47(6):1148-55. PubMed ID: 18607872
[TBL] [Abstract][Full Text] [Related]
3. Chemotherapy for patients with two favourable subsets of unknown primary carcinoma: active, but how effective?
Pentheroudakis G; Briasoulis E; Karavassilis V; Fountzilas G; Xeros N; Samelis G; Samantas E; Pavlidis N
Acta Oncol; 2005; 44(2):155-60. PubMed ID: 15788295
[TBL] [Abstract][Full Text] [Related]
4. Management of carcinoma of unknown primary site (CUP), any changes?
Hansen HH; Daugaard G
Ann Oncol; 2001 Apr; 12(4):431-2. PubMed ID: 11398871
[No Abstract] [Full Text] [Related]
5. Liver metastases from cancer of unknown primary (CUPL): a retrospective analysis of presentation, management and prognosis in 49 patients and systematic review of the literature.
Lazaridis G; Pentheroudakis G; Fountzilas G; Pavlidis N
Cancer Treat Rev; 2008 Dec; 34(8):693-700. PubMed ID: 18584969
[TBL] [Abstract][Full Text] [Related]
6. Site-specific Chemotherapy Based on Predicted Primary Site by Pathological Profile for Carcinoma of Unknown Primary Site.
Hasegawa H; Ando M; Yatabe Y; Mitani S; Honda K; Masuishi T; Narita Y; Taniguchi H; Kadowaki S; Ura T; Muro K
Clin Oncol (R Coll Radiol); 2018 Oct; 30(10):667-673. PubMed ID: 30196846
[TBL] [Abstract][Full Text] [Related]
7. Second-line chemotherapy in patients with primary unknown cancer.
Ono M; Ando M; Yonemori K; Yamamoto H; Hirata T; Shimizu C; Tamura K; Katsumata N; Fujiwara Y
J Cancer Res Clin Oncol; 2011 Aug; 137(8):1185-91. PubMed ID: 21559815
[TBL] [Abstract][Full Text] [Related]
8. Management of "unfavourable" carcinoma of unknown primary site: synthesis of recent literature.
Amela EY; Lauridant-Philippin G; Cousin S; Ryckewaert T; Adenis A; Penel N
Crit Rev Oncol Hematol; 2012 Nov; 84(2):213-23. PubMed ID: 22503530
[TBL] [Abstract][Full Text] [Related]
9. Management of patients with cancer of unknown primary site.
Hainsworth JD; Greco FA
Oncology (Williston Park); 2000 Apr; 14(4):563-74; discussion 574-6, 578-9. PubMed ID: 10826316
[TBL] [Abstract][Full Text] [Related]
10. Treatment and prognosis of metastatic carcinoma of unknown primary: analysis of 100 patients.
Alberts AS; Falkson G; Falkson HC; van der Merwe MP
Med Pediatr Oncol; 1989; 17(3):188-92. PubMed ID: 2747591
[TBL] [Abstract][Full Text] [Related]
11. [Clinical characteristics of cancer of unknown primary (CUP)--a summary of 22 cases].
Kato S; Yasuda K; Nishino Y; Ohori H; Takahashi M; Takahashi S; Yamaura G; Ohtsuka K; Kakudo Y; Chiba N; Shimodaira H; Sakayori M; Kato S; Suzuki T; Murakawa Y; Gamoh M; Shibata H; Yoshioka T; Ishioka C
Gan To Kagaku Ryoho; 2007 Aug; 34(8):1227-31. PubMed ID: 17687203
[TBL] [Abstract][Full Text] [Related]
12. Molecular assignment of tissue of origin in cancer of unknown primary may not predict response to therapy or outcome: a systematic literature review.
Pentheroudakis G; Greco FA; Pavlidis N
Cancer Treat Rev; 2009 May; 35(3):221-7. PubMed ID: 19046817
[TBL] [Abstract][Full Text] [Related]
13. Cancer of unknown primary site: review of consecutive cases at the National Cancer Center Hospital of Japan.
Yakushiji S; Ando M; Yonemori K; Kohno T; Shimizu C; Katsumata N; Fujiwara Y
Int J Clin Oncol; 2006 Dec; 11(6):421-5. PubMed ID: 17180509
[TBL] [Abstract][Full Text] [Related]
14. Cancer of unknown primary site.
Pavlidis N; Pentheroudakis G
Lancet; 2012 Apr; 379(9824):1428-35. PubMed ID: 22414598
[TBL] [Abstract][Full Text] [Related]
15. Bone metastasis and poor performance status are prognostic factors for survival of carcinoma of unknown primary site in patients treated with systematic chemotherapy.
Kodaira M; Takahashi S; Yamada S; Ueda K; Mishima Y; Takeuchi K; Yamamoto N; Ishikawa Y; Yokoyama M; Saotome T; Terui Y; Hatake K
Ann Oncol; 2010 Jun; 21(6):1163-1167. PubMed ID: 20019088
[TBL] [Abstract][Full Text] [Related]
16. Long-term remission in a patient with carcinoma of unknown primary site.
Jentsch-Ullrich K; Kalinski T; Roessner A; Franke A; Mohren M
Chemotherapy; 2006; 52(1):12-5. PubMed ID: 16340191
[TBL] [Abstract][Full Text] [Related]
17. Poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown origin: favorable subsets of patients with unknown-primary carcinoma?
Lenzi R; Hess KR; Abbruzzese MC; Raber MN; Ordoñez NG; Abbruzzese JL
J Clin Oncol; 1997 May; 15(5):2056-66. PubMed ID: 9164218
[TBL] [Abstract][Full Text] [Related]
18. Unknown primary carcinoma: randomised studies are needed to identify optimal treatments and their benefits.
Farrugia DC; Norman AR; Nicolson MC; Gore M; Bolodeoku EO; Webb A; Cunningham D
Eur J Cancer; 1996 Dec; 32A(13):2256-61. PubMed ID: 9038607
[TBL] [Abstract][Full Text] [Related]
19. New rising entities in cancer of unknown primary: Is there a real therapeutic benefit?
Rassy E; Parent P; Lefort F; Boussios S; Baciarello G; Pavlidis N
Crit Rev Oncol Hematol; 2020 Mar; 147():102882. PubMed ID: 32106012
[TBL] [Abstract][Full Text] [Related]
20. Taxane-based chemotherapy for patients with carcinoma of unknown primary site.
Greco FA; Gray J; Burris HA; Erland JB; Morrissey LH; Hainsworth JD
Cancer J; 2001; 7(3):203-12. PubMed ID: 11419028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
